IPD
ImpediMed Limited
🇦🇺 ASX
🩺 HEALTH CARE
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
-2.16%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
11
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 83 full-time employees. The company went IPO on 2007-10-24. The firm uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The firm designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. SOZO uses its BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.
📈 Performance
Price History
-96.36%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🍃 Environmental, Social and Governance scores ℹ️
🌳
Environmental Score
10
A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution
⚖️
Governance Score
41
An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.
🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IPD
11
📊 Total Capital Earnings
$11K
🔃 Average investment frequency
24 weeks
💵 Average investment amount
$2,048
⏰ Last time a customer invested in IPD
126 days
IPD investor breakdown
💵 Income of investors
More than 200k
7%
150k - 200k
100k - 150k
13%
50k - 100k
33%
Less than 50k
40%
👶 Age of investors
18 - 25
26 - 34
36%
35 - 90
64%
🙋 Legal gender of investors
Female
45%
Male
55%
Pearlers who invest in IPD also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
9.25%
📊 Share price
$96.77 AUD
📈 HIGH PRICE GROWTH
💸 FINANCIALS
🇦🇺 AUSTRALIA
🧱 MATERIALS
⛳️ DIVERSIFIED
Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. The company develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. The company operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.
🙌 Performance (5Yr p.a)
426.78%
📊 Share price
$25.69 AUD
🧬 BIOTECHNOLOGY
BHP Group Ltd. engages in the exploration, development, production and processing of iron ore, metallurgical coal, and copper. The company is headquartered in Melbourne, Victoria and currently employs 39,729 full-time employees. The firm is a producer of commodities, including iron ore, copper, nickel, potash and metallurgical (steelmaking) coal. The company is focused on offering a range of resources, which provides copper for renewable energy; nickel for electric vehicles; potash for sustainable farming, and iron ore and metallurgical coal for the steel needed for global infrastructure and the energy transition. Its segments include Copper, Iron Ore, and Coal. Its Copper segment is engaged in mining of copper, silver, zinc, molybdenum, uranium, and gold. Its Iron Ore segment is engaged in mining of iron ore. Its Coal segment is engaged in mining of metallurgical coal and energy coal. The firm is also focused on operating Olympic Dam, Prominent Hill, and Carrapateena underground copper-gold mines in South Australia. Its operations are situated in Australia, Europe, China, Japan, India, South Korea, rest of Asia, North America, South America, and others.
🙌 Performance (5Yr p.a)
7.27%
📊 Share price
$36.48 AUD
⛏️ MINING
💰 HIGH DIVIDEND
⚖️ HIGH GOVERNANCE
Catapult Group International Ltd. engages in the development and supply of wearable athlete tracking and analytics solutions. The company is headquartered in Prahan, Victoria. The company went IPO on 2014-12-19. The Company’s products are designed to optimize performance, avoid injury, and improve return to play. The firm operates through three segments: Performance & Health, Tactics & Coaching and Media & Other. The Performance & Health segment is engaged in the design, development and supply of wearable technology and athlete monitoring software solutions to sports teams, athletes, and the prosumer market. The Tactics & Coaching segment is engaged in the design, development and supply of video analysis, editing, and publishing software solutions to sports teams. The Media & Other segment provides media licensing, athlete management and professional services to customers. Its wearable and video solutions are provided to elite clients on both a subscription and upfront capital sales basis. The firm works with more than 3,800 elite teams in over 40 sports.
🙌 Performance (5Yr p.a)
57.08%
📊 Share price
$3.70 AUD
🤖 TECHNOLOGY
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
17.17%
📊 Share price
$43.32 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
🇺🇸 UNITED STATES
⛳️ DIVERSIFIED
Want more shares? Try these...
🕊️
Social Score
59
An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.